


Claims

What is claimed is:


1. A method of treating a prion disease in a human in need thereof comprising administering a therapeutically effective amount of a compound of formula IV or a pharmaceutically acceptable salt thereof:



(IV)


or a stereoisomer thereof.

2. The method of claim 1, wherein the method of treating the prion disease is a method of treating the dementia that is symptomatic of the prion disease.
3. The method of claim 1, wherein the prion disease is variant Creutzfeldt-Jakob Disease.
4. The method of claim 1, wherein the prion disease is Creutzfeldt-Jakob Disease.
5. The method of claim 1, wherein the prion disease is Gerstmann-Sträussler-Scheinker disease.
6. The method of claim 1, wherein the prion disease is fatal familial insomnia.
7. The method of claim 1, wherein the compound of formula IV is




or a stereoisomer thereof.

8. The method of claim 1, wherein the compound of formula IV is a compound of formula VI or a pharmaceutically acceptable salt thereof:



5 (VI).

9. The method of claim 1, wherein the compound of formula IV is a compound of formula VII or a pharmaceutically acceptable salt thereof:



(VII).

10 10. The method of claim 1, wherein the compound of formula IV is administered in an amount of about 1 mg to about 100 mg.

11. The method of claim 10, wherein the compound of formula IV is administered in an amount of about 5 mg to about 10 mg.

12. The method of claim 1, wherein the compound of formula IV is administered in an amount of about 5 milligrams.

13. The method of claim 1, wherein the compound of formula IV is administered in an amount of about 10 milligrams.

14. The method of claim 1, wherein the compound of formula IV is orally administered.

20 15. The method of claim 14, wherein the compound of formula IV is orally


administered in the form of a tablet.

16. The method of claim 1, further comprising administering a pharmaceutically acceptable carrier.

17. The method of claim 1, further comprising administering a therapeutically effective amount of mepacrine or a pharmaceutically acceptable salt thereof, and/or chlorpromazine or a pharmaceutically acceptable salt thereof.

18. A method of treating a prion disease in a human in need thereof comprising administering a therapeutically effective amount of at least one cholinesterase inhibitor.


19. A composition comprising a therapeutically effective amount of at least one compound selected from mepacrine or a pharmaceutically acceptable salt thereof, and chlorpromazine or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a compound of formula IV or a pharmaceutically acceptable salt thereof:



(IV)

or a stereoisomer thereof.


20. A combination comprising a therapeutically effective amount of at least one compound selected from mepacrine or a pharmaceutically acceptable salt thereof, and chlorpromazine or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a compound of formula IV or a pharmaceutically acceptable salt thereof:



(IV)

or a stereoisomer thereof.

21. A kit comprising a therapeutically effective amount of at least one
 5 compound selected from mepacrine or a pharmaceutically acceptable salt thereof, and
 chlorpromazine or a pharmaceutically acceptable salt thereof; and a therapeutically
 effective amount of a compound of formula IV or a pharmaceutically acceptable salt
 thereof:



(IV)

or a stereoisomer thereof.